Sumeet Singh
Senior Director, HEOR
Expertise:
Sumeet Singh is a Senior Director at EVERSANA where he leads HEOR projects for Canadian and global pharmaceutical clients. Prior to joining EVERSANA, Sumeet held various leadership positions at the Canadian Agency for Drugs and Technologies in Health (CADTH). He has 18 years of experience in health technology assessment and health economics. Sumeet completed a master’s degree in Health Research Methodology from McMaster University and a bachelor’s degree in Pharmacy from the University of Toronto.
Articles by Sumeet Singh
New Insights into Brain Volume Loss in MS
We are excited to announce that members of the EVERSANA team have contributed to a significant publication in BMC Neurology. The study, titled “Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies,” provides valuable insights into the effects of various treatments on brain volume loss (BVL) in patients with relapsing multiple sclerosis. BVL may be associated with faster disability progression for patients with MS, therefore the finding of important differences in BVL rates between various disease-modifying treatments (DMTs) could have important implications for patients, clinicians and policymakers. Special recognition goes to our esteemed authors: from EVERSANA, along with their coauthors from the University of Buffalo, Janssen Scientific […]
Canadian Market Access Success Starts With the Right Partner
The Canadian market access and reimbursement environment is in an era of unprecedented change. HTA bodies are transforming their organizations to make review processes more efficient and give Canadians faster access to new drugs (e.g., Target Zero, time-limited recommendations, streamlined economic reviews, rolling reviews). At the same time, Canadian drug prices continue to be regulated under PMPRB’s interim guidelines, the pCPA is increasingly leveraging the Targeted Negotiation Process, and the federal government has taken the first steps toward National Pharmacare. This rapidly changing environment brings both opportunities and potential threats for those seeking to commercialize innovative therapies in Canada. More than ever, market access success depends on having the right […]
Navigating an Ever-evolving Canadian Market Access and Reimbursement Environment
These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes and key stakeholders, careful strategic planning, sound tactics and skilled execution. Some key steps and considerations to maximize the chances of timely reimbursement are as follows: Up to 18 months pre-NOC: Information-gathering and early strategy work Conduct a market access landscape assessment Identify unmet needs and potential place in therapy Perform a strategic review of the clinical evidence to identify gaps that may pose a risk during HTA review, and potential mitigation strategies Evaluate […]